Computer aided analysis of skin lesions

Effective screening to detect the skin cancer accurately in the early stage is essential for reducing the mortality of skin cancer. Surface features, such as texture and pigmentation area from the surface, epi-illumination images of the skin lesions have been well correlated to detect skin cancer. An increase in the lesion\u27s subsurface blood volume has been correlated to early diagnosis of malignant melanoma. A method for estimating the optimal features is obtained. The optimal features help in accurately classify the skin lesion in various grades. To make the process faster these optimal features are clustered. The optimal clusters are obtained by genetic algorithm. The optimal cluster centers act as input to the SVM classifier and the kernel parameters are obtained. Finally, parameters of the kernel function are optimized by genetic algorithm, which help in classifying the skin lesions into various grades leading to early diagnosis of skin cancer

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia

IntroductionChronological aging is a well-recognized diagnostic and prognostic factor in multiple cancer types, yet the role of biological aging in manifesting cancer progression has not been fully explored yet.MethodsGiven the central role of chronological aging in prostate cancer and AML incidence, here we investigate a tissue-specific role of biological aging in prostate cancer and AML progression. We have employed Cox proportional hazards modeling to associate biological aging genes with cancer progression for patients from specific chronological aging groups and for patients with differences in initial cancer aggressiveness.ResultsOur prostate cancer-specific investigations nominated four biological aging genes (CD44, GADD45B, STAT3, GFAP) significantly associated with time to disease progression in prostate cancer in Taylor et al. patient cohort. Stratified survival analysis on Taylor dataset and validation on an independent TCGA and DKFZ PRAD patient cohorts demonstrated ability of these genes to predict prostate cancer progression, especially for patients with higher Gleason score and for patients younger than 60 years of age. We have further tested the generalizability of our approach and applied it to acute myeloid leukemia (AML). Our analysis nominated three AML-specific biological aging genes (CDC42EP2, CDC42, ALOX15B) significantly associated with time to AML overall survival, especially for patients with favorable cytogenetic risk score and for patients older than 56 years of age.DiscussionComparison of the identified PC and AML markers to genes selected at random and to known markers of progression demonstrated robustness of our results and nominated the identified biological aging genes as valuable markers of prostate cancer and AML progression, opening new avenues for personalized therapeutic management and potential novel treatment investigations

Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer

Therapeutic resistance is a central problem in clinical oncology. We have developed a systematic genome-wide computational methodology to allow prioritization of patients with favorable and poor therapeutic response. Our method, which integrates DNA methylation and mRNA expression data, uncovered a panel of 5 differentially methylated sites, which explain expression changes in their site-harboring genes, and demonstrated their ability to predict primary resistance to androgen-deprivation therapy (ADT) in the TCGA prostate cancer patient cohort (hazard ratio = 4.37). Furthermore, this panel was able to accurately predict response to ADT across independent prostate cancer cohorts and demonstrated that it was not affected by Gleason, age, or therapy subtypes. We propose that this panel could be utilized to prioritize patients who would benefit from ADT and patients at risk of resistance that should be offered an alternative regimen. Such approach holds a long-term objective to build an adaptable accurate platform for precision therapeutics. Keywords: Therapeutic resistance, DNA methylation, mRNA expression, Epigenomics, Androgen-deprivation, Prostate cance

A chemodosimeter for the ratiometric detection of hydrazine based on return of ESIPT and its application in live-cell imaging

A probe based on 2-(2′-hydroxyphenyl) benzothiazole (HBT) has been synthesized and used for the ratiometric detection of hydrazine. The probe is designed in such a way that the excited state intramolecular proton transfer (ESIPT) of the HBT moiety gets blocked. The chemodosimetric approach of hydrazine to the probe results in the recovery of the ESIPT by removal of a free HBT moiety through subsequent substitution, cyclization, and elimination processes. The probe is successfully demonstrated to enable the detection of hydrazine in live cells

A Chemodosimeter for the Ratiometric Detection of Hydrazine Based on Return of ESIPT and Its Application in Live-Cell Imaging

A probe based on 2-(2′-hydroxyphenyl) benzothiazole (HBT) has been synthesized and used for the ratiometric detection of hydrazine. The probe is designed in such a way that the excited state intramolecular proton transfer (ESIPT) of the HBT moiety gets blocked. The chemodosimetric approach of hydrazine to the probe results in the recovery of the ESIPT by removal of a free HBT moiety through subsequent substitution, cyclization, and elimination processes. The probe is successfully demonstrated to enable the detection of hydrazine in live cells

NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.

Mitochondria provide the first line of defense against the tumor-promoting effects of oxidative stress. Here we show that the prostate-specific homeoprotein NKX3.1 suppresses prostate cancer initiation by protecting mitochondria from oxidative stress. Integrating analyses of genetically engineered mouse models, human prostate cancer cells, and human prostate cancer organotypic cultures, we find that, in response to oxidative stress, NKX3.1 is imported to mitochondria via the chaperone protein HSPA9, where it regulates transcription of mitochondrial-encoded electron transport chain (ETC) genes, thereby restoring oxidative phosphorylation and preventing cancer initiation. Germline polymorphisms of NKX3.1 associated with increased cancer risk fail to protect from oxidative stress or suppress tumorigenicity. Low expression levels of NKX3.1 combined with low expression of mitochondrial ETC genes are associated with adverse clinical outcome, whereas high levels of mitochondrial NKX3.1 protein are associated with favorable outcome. This work reveals an extranuclear role for NKX3.1 in suppression of prostate cancer by protecting mitochondrial function. SIGNIFICANCE: Our findings uncover a nonnuclear function for NKX3.1 that is a key mechanism for suppression of prostate cancer. Analyses of the expression levels and subcellular localization of NKX3.1 in patients at risk of cancer progression may improve risk assessment in a precision prevention paradigm, particularly for men undergoing active surveillance.See related commentary by Finch and Baena, p. 2132.This article is highlighted in the In This Issue feature, p. 2113

A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance

Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of metastasis in vivo. Here we show that NPK(EYFP) mice (for Nkx3.1(CreERT2/+); Pten(flox/flox); Kras(LSL-G12D/+); R26R-CAG-(LSL-EYFP/+)) develop prostate cancer with a high penetrance of metastasis to bone, thereby enabling detection and tracking of bone metastasis in vivo and ex vivo. Transcriptomic and whole-exome analyses of bone metastasis from these mice revealed distinct molecular profiles conserved between human and mouse and specific patterns of subclonal branching from the primary tumor. Integrating bulk and single-cell transcriptomic data from mouse and human datasets with functional studies in vivo unravels a unique MYC/RAS co-activation signature associated with prostate cancer metastasis. Finally, we identify a gene signature with prognostic value for time to metastasis and predictive of treatment response in human patients undergoing androgen receptor therapy across clinical cohorts, thus uncovering conserved mechanisms of metastasis with potential translational significance